Announcements
- Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
- Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
- Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
- Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
- Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
More ▼
Key statistics
On Wednesday, Xenon Pharmaceuticals Inc (XP0:STU) closed at 33.40, 29.46% above the 52 week low of 25.80 set on Nov 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.40 |
---|---|
High | 33.40 |
Low | 33.40 |
Bid | 33.20 |
Offer | 35.80 |
Previous close | 34.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 75.47m |
Free float | 74.29m |
P/E (TTM) | -- |
Market cap | 2.76bn USD |
EPS (TTM) | -2.71 USD |
Data delayed at least 15 minutes, as of Jul 03 2024.
More ▼